Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Removes waste products (e.g., urea, creatinine) and excess electrolytes via diffusion and ultrafiltration across the peritoneal membrane; dextrose acts as osmotic agent to generate ultrafiltration.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges daily, as part of continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
None Documented
None Documented
Not applicable; dextrose is rapidly metabolized (half-life ~2-5 min), electrolytes are distributed and excreted renally with half-life dependent on renal function.
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Renal: 100% (electrolytes and dextrose are completely reabsorbed or metabolized; water is excreted renally). Biliary/fecal: 0%.
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution